Product Name: CLCN7 Antibody
Species Reactivity: Human
Tested Applications: IF, IHC-P, WB
Applications: For WB starting dilution is: 1:1000For IHC-P starting dilution is: 1:10~50For IF starting dilution is: 1:10~50
User Note: Optimal dilutions for each application to be determined by the researcher.
Predicted Molecular Weight: 89 kDa
Immunogen: This CLCN7 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 692-720 amino acids from the C-terminal region of human CLCN7.
Host Species: Rabbit
Purification: This antibody is purified through a protein A column, followed by peptide affinity purification.
Physical State: Liquid
CAS NO.: 287714-41-4
Product: Rosuvastatin
Buffer: Supplied in PBS with 0.09% (W/V) sodium azide.
Concentration: 0.5 mg/ml
Storage Conditions: Store at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Clonality: Polyclonal
Conjugate: Unconjugated
Alternate Names: H(+)/Cl(-) exchange transporter 7, Chloride channel 7 alpha subunit, Chloride channel protein 7, ClC-7, CLCN7
Accession NO.: P51798
Protein Ino: 12644301
Official Symbol: CLCN7
Geneid: 1186
Background: The product of this gene belongs to the CLC chloridechannel family of proteins. Chloride channels play important rolesin the plasma membrane and in intracellular organelles. This geneencodes chloride channel 7. Defects in this gene are the cause ofosteopetrosis autosomal recessive type 4 (OPTB4), also calledinfantile malignant osteopetrosis type 2 as well as the cause ofautosomal dominant osteopetrosis type 2 (OPTA2), also calledautosomal dominant Albers-Schonberg disease or marble diseaseautosoml dominant. Osteopetrosis is a rare genetic diseasecharacterized by abnormally dense bone, due to defective resorptionof immature bone. OPTA2 is the most common form of osteopetrosis,occurring in adolescence or adulthood.
PubMed ID:http://aac.asm.org/content/36/5/1049.abstract
